The purpose of this article is to review the current therapy of Addison's disease and to highlight recent developments in this field.
INTRODUCTION
Few principles in medicine could be simpler than that of replacing the adrenocortical hormones to restore health to an individual with adrenal failure. However, several studies show that patients with Addison's disease (primary adrenocortical failure) have poor quality of life, lessened ability to hold down employment and increased morbidity and mortality [1] [2] [3] . Thus, current hormone replacement for adrenal insufficiency is imperfect and we need to understand the reasons for this and develop improved therapies.
In health, pulsatile adrenocorticotropic hormone (ACTH) secretion from the pituitary starts at 03.00 h increasing to a zenith around 07.00 h, with a concordant but slightly delayed rise in adrenal cortisol secretion. During the late morning and early afternoon, ACTH pulse amplitude decreases, leading to reduced levels of serum cortisol by the late afternoon and evening. Although an understanding of this circadian variation in cortisol secretion is intuitively the key to optimizing glucocorticoid replacement in patients with Addison's disease, [4] it must also be borne in mind that tissue glucocorticoid receptor occupancy is not directly related to the simultaneous serum cortisol concentration. Similarly, differences in circulating cortisol binding globulin concentration and in cortisol disposal influence serum cortisol concentrations in different physiological and disease states [5] . This article reviews current approaches to the therapy of adrenal insufficiency and outlines recent developments and future possibilities in the field.
BACKGROUND TO ADDISON'S DISEASE
Addison's disease is a rare endocrinopathy with a prevalence of approximately 1 per 8000 in European whites, and a male to female ratio of 1 : 2. Although the majority of patients still have a first presentation with symptoms of acute steroid insufficiency such as hypotensive collapse or vomiting, in retrospect, most individuals have been unwell with weight loss, anorexia, fatigue or postural hypotension for many months, [6] often with increased skin pigmentation noted as the earliest feature [7] . In developed nations, an autoimmune attack directed against the adrenal steroidogenic enzymes, including steroid 21-hydroxylase, accounts for about 85% of cases [1] . However, tuberculosis remains a significant cause, particularly in developing countries. A detailed account of pathogenesis can be found in a recent review [8] .
GLUCOCORTICOID REPLACEMENT
The cornerstone of glucocorticoid replacement in Addison's disease is oral hydrocortisone, typically 15-25 mg daily, taken in divided doses. This total daily hydrocortisone requirement is dependent upon body surface area with the measured cortisol production rate of about 6 mg/m 2 /day [9] . The first dose, generally 10 mg, should be taken immediately on wakening, with the aim of mimicking the physiological pattern of secretion. A further one or two smaller doses should be taken at 4 to 6-hourly intervals, with the final dose taken more than 4 h before bedtime. Typical dose regimens should be tailored for body size/weight and are summarized in Table 1 , however these are indicative only, as individual absorption and disposal kinetics are quite variable. For smaller adults (<65 kg), a regimen of 10 mg on waking and 5 mg between midday and 14.00 h, or in three doses such as 10, 5 and 2.5 mg taken at 07.00, 12.00 and 16.00 h, respectively, are suitable. Higher doses of hydrocortisone may be required for larger individuals, but it is rarely necessary to treat people with more than a total daily dose of 25 mg, providing mineralocorticoid replacement and salt intake are adequate.
Alternative oral steroids can be used, with a single or twice-daily dose of prednisolone or prednisone (e.g. 3 to 6 mg taken once; or 3 mg on waking, 1 mg at midday and so on) being acceptable to many patients. In some parts of the world, cortisone acetate is still widely used as a satisfactory replacement for adrenal insufficiency, but this first undergoes hepatic activation to cortisol leading to a slightly slower onset of action. Although it is theoretically possible to use a variety of other glucocorticoids, in practice, medications such as dexamethasone, beclomethasone or deflazacort have a long half-life and can easily result in significant overdosage.
On the crudest level, features such as weight gain, development of glucose intolerance, moon face, thin skin, decreased bone mineral density or osteoporotic fractures indicate overdosage with glucocorticoid. Conversely, anorexia, weight loss, retching or vomiting, fatigue, breathlessness and persistent or increasing pigmentation indicate insufficient replacement. However, even in the absence of these gross features, fine tuning of glucocorticoid doses is important, as even slight glucocorticoid overexposure on a chronic basis will increase the risk of complications. Patients should be directly asked about each dose of steroid they take during the day: how they feel immediately before it, whether they ever miss this dose and whether they regularly need to take additional doses at any
KEY POINTS
Excellent patient engagement and steroid education is a key to allowing people with Addison's disease to safely manage their condition, day-to-day.
Both modified-release hydrocortisone tablets and continuous subcutaneous hydrocortisone infusions offer closer approximations to healthy plasma cortisol rhythms than multidose, immediate-release oral hydrocortisone.
Greater clinical experience with these novel replacement therapies needs to be gained for their role in the management of adrenal insufficiency to be established.
Fine-tuning of mineralocorticoid replacement and salt intake in Addison's patients is important for adrenal crisis prevention and optimal well-being, and is often neglected by physicians.
There is durable residual adrenal function in a proportion of patients with Addison's disease, and this is a future therapeutic target. Morning symptoms of nausea, retching or anorexia are common amongst individuals with adrenal insufficiency, and breakfast is frequently delayed or omitted altogether. These symptoms represent the effect of glucocorticoid deficiency at the time of waking and may be combated by asking the patient to take half or the full first dose of hydrocortisone 2 h before getting out of bed, by setting an alarm. Alternatively, a change to taking the last dose of glucocorticoid later in the day or a switch to a longer acting steroid such as prednisolone may help improve these symptoms. Dipping of energy levels or 'low spots' during the day are also frequently reported by Addisonian patients, and if these follow a predictable pattern, then the timings of the hydrocortisone dose should be adjusted accordingly. If this fails, a swap to an equivalent dose of prednisolone (one-quarter of the hydrocortisone dose in mg) frequently helps with this problem. Lastly, some Addisonian patients will feel tired in the early evening and routinely go to bed prematurely (e.g. 20.00 h). This needs to be specifically asked about and dosages adjusted to allow the person to have a normal social and family life. Conversely, insomnia or going to bed very late signify that the last dose of hydrocortisone of the day should be taken at an earlier time, or could potentially be reduced or omitted. Plasma ACTH concentrations rise physiologically during sleep in adrenally insufficient patients, but the amplitude is very variable and cannot be used to guide dosing of glucocorticoid.
Alternative oral glucocorticoid replacement
With an understanding of the daily physiological rhythm of cortisol secretion, two groups have taken parallel approaches to formulating modified-release hydrocortisone preparations that more closely mimic this natural pattern. The best-studied preparation is termed Plenadren and this has recently been approved by the European Medicines Agency and launched in Europe. It consists of a core of delayed release, compressed hydrocortisone, with a surrounding immediate-release component. It is designed for once-daily administration and is available in 20 and 5 mg strengths, although bioavailability is about 20% less than with conventional immediate-release hydrocortisone. Following a single oral dose, the peak serum cortisol achieved is rapid and comparable to that with conventional hydrocortisone. However, without multiple additional daily doses, the afternoon and evening cortisol exposure is significantly lower and better mirrors the physiological situation (Fig. 1) . A crossover study [10 & ] of 64 individuals with Addison's disease showed that there were modest improvements in blood pressure and a reduction in weight during 12 weeks of Plenadren therapy as compared with three-times daily hydrocortisone at the same dose. Importantly, a small number of patients with coexisting diabetes (n ¼ 9) in this study also had significant improvements in glycaemic control, with a mean reduction in HbA1c of 0.6% during 12 weeks of Plenadren therapy compared with conventional treatment. Not surprisingly, 85% of patients preferred taking a single dose over threetimes daily hydrocortisone, and 92% opted to stay on the medication following the initial trial [10 & ]. The role of this new formulation in clinical practice is just starting to be evaluated, and it remains unclear what proportion of the apparent metabolic benefits are due to its reduced bioavailability (hence effectively lower hydrocortisone dose) rather than the more physiological pattern of cortisol exposure. An additional product, Chronocort, containing microparticulate hydrocortisone with delayed absorption is also currently in development [11 & ]. This differs from Plenadren in that it is designed to be taken twice daily, the delayed release of the bedtime dose simulating the normal rise in cortisol secretion during sleep.
Subcutaneous hydrocortisone (pump) therapy
In line with the principle of mimicking the physiological secretion pattern of cortisol, attempts to improve glucocorticoid therapy have extended to the use of continuous subcutaneous hydrocortisone infusions (CSHIs), administered using proprietary insulin pumps. A feasibility study of seven patients with Addison's disease demonstrated that physiological levels of salivary cortisol could be achieved using a continuous subcutaneous hydrocortisone regimen consisting of four-dose phases, amounting to a total daily dose of around 10 mg/m 2 (range 8-15 mg/m 2 ) of body surface area [12] . Patient acceptability was high, and two out of five patients opted to stay on the subcutaneous infusion following the study. Subsequent to this study, a further 33 patients have been studied in a cross-over design, comparing thrice-daily oral hydrocortisone and CSHI over 12 weeks. During a 24-h period, individuals had higher waking salivary cortisol levels and better control of overnight ACTH levels during pump therapy [13 & ]. Disease-specific quality of life was improved in the infusion group, but there was no difference in anthropometric parameters or blood pressure [13 & ]. Use of subcutaneous hydrocortisone has many parallels to the use of insulin infusion pumps in type 1 diabetes and could have significant advantages for Addison's disease patients with daytime fluctuations in energy levels on oral medication. However, more detailed evaluation and longer-term experience are now required to fully evaluate the benefits of this approach and its role in day-to-day practice.
Mineralocorticoid and sodium replacement
Aldosterone secretion is essential for maintenance of bodily sodium and hence fluid balance and blood pressure. Unlike glucocorticoid replacement, patients can omit to take their mineralocorticoid medication and feel well for several days before the body's sodium reserve is depleted. This may lead to poor compliance, particularly when compared with the almost immediate ill-effects that patients feel if doses of glucocorticoid are not taken. In addition, physicians may be lax at optimizing mineralocorticoid replacement, leading to patient feelings of being chronically light-headed, weak or 'washedout', as well as abnormal cravings for salty food.
Mineralocorticoid replacement is taken as fludrocortisone (Florinef) tablets, generally as a single daily dose of 50-200 mg. However, children, younger adults and very physically active individuals may need significantly higher fludrocortisone doses, occasionally up to 500 mg daily. In addition, individuals with Addison's disease must be specifically instructed to take salt and sodium-rich foods ad libitum, and to ignore healthy eating advice to reduce salt intake that is applicable to the rest of the population. Suspicions of insufficient mineralocorticoid replacement may be raised on clinical grounds, and enquiries about feelings of light-headedness, fainting, nocturia or urinary frequency, salt cravings and intake of salty foods including salt itself, potato chips, salted nuts, olives and soy sauce should be made. Strangely, many patients with Addison's disease will also crave for sour/acidic foodstuffs such as lemons, vinegar or pickles. Assessment of blood pressure including for postural change, and measurement of serum sodium and potassium should be undertaken at regular intervals. In addition, measurement of plasma renin, either by concentration (mass) or by enzymatic activity should be made, although this is primarily a marker of plasma volume (renal perfusion) rather than directly of sodium state. Thus, it is possible for an Addisonian patient to have frank hyponatraemia, but a normal plasma renin activity. Therefore, an elevated plasma renin indicates the need for an increase in fludrocortisone dose, although a normal renin concentration is still consistent with a degree of sodium depletion. Conversely, ankle or leg swelling, hypernatraemia and hypokalaemia indicate fludrocortisone overtreatment. As a general guide, it is satisfactory to have an ambulant renin activity within the reference range, but avoiding a fully suppressed (<0.2 ng/ml/h) value. In the presence of hypertension, consideration should be given to cautious reduction of the fludrocortisone dose; however, there is a high probability of adrenal crisis due to salt depletion if mineralocorticoid replacement is stopped completely. Initial management of essential hypertension should therefore be with calcium channel blockers or angiotensin-converting enzyme (ACE)-inhibitors; diuretics should be avoided.
Intercurrent illness and emergency management
Patient education is a key part of the management of Addison's disease, and people with adrenal insufficiency need to be empowered to take control of their own medical management, even in the presence of nonexpert health professionals. A steroid card and medical alert patient identification jewellery are necessary in the case of unconsciousness. Furthermore, patients should carry additional hydrocortisone tablets and have a vial of injectable hydrocortisone, with needle and syringe available at all times. As well as the affected person, it is advisable for the partner/spouse and immediate family members to be trained in administration of parenteral hydrocortisone. Interestingly, a recent study has found that the delay to achieving a serum cortisol concentration greater than 36 mg/dl (1000 nmol/l) following subcutaneously administered hydrocortisone was 22 min, compared with 11 min following intramuscular administration [14 & ]. Although the individuals were not unwell (i.e. haemodynamically compromised) at the time of the trial, this suggests that subcutaneous administration of hydrocortisone is likely to give adequate levels in most circumstances. In addition, the subcutaneous route was preferred by more than 90% of patients than the intramuscular route [14 & ].
In the presence of any intercurrent illness such as a common cold, influenza or minor infection, that is sufficient to raise the temperature to more than 37.5 o C or to make the person feel systemically unwell, then the daily hydrocortisone dosage should be doubled and hydration carefully managed. Two-thirds of adrenal crises and emergency hospital admissions are owing to intercurrent gastrointestinal disturbance [15, 16] ; therefore, patients should be meticulous about doubling hydrocortisone doses if they develop diarrhoea. In the presence of vomiting, double the regular oral hydrocortisone dose should be taken immediately with a sip of water, and if there is further vomiting within 30 min of this oral dose, then an intramuscular injection of hydrocortisone is warranted [17 & ].
Adrenal crisis is a life-threatening emergency that requires immediate recognition and prompt treatment. However, only around 8% of Addison's disease patients will experience an adrenal crisis each year, and around 50% of individuals have never had such a crisis [15, 16] . As mentioned above, gastrointestinal disturbance is the commonest precipitating factor, but infections, surgical procedures carried out with insufficient steroid cover and accidental injuries are less common triggers. Even psychological distress, such as attending a funeral, has been reported to precipitate adrenal crisis. Once adrenal crisis is recognized, immediate intravenous (i.v.) or intramuscular hydrocortisone 100 mg should be administered, followed by a litre of i.v isotonic saline (0.9%) over 30 min. Full details of resuscitative measures are given in this recent European Consensus statement [17 & ].
Disease-modifying therapies
With the advent of the biological agents as diseasemodifying therapy for inflammatory arthritis and their experimental use in several other autoimmune conditions including type 1 diabetes [18] , our group undertook a pilot study of immunomodulatory therapy in newly diagnosed patients with autoimmune Addison's disease [19 & ]. Addison's disease has several attractions as a disease model: firstly, adrenal glands have intrinsic plasticity due to ACTH-responsive stem or progenitor cells located in the subcapsular region [20] . Thus, it is well established that excess ACTH secretion during Cushing's disease or in steroidogenic enzyme defects ('congenital adrenal hyperplasia') leads to adrenal hyperplasia. Conversely, adrenal atrophy ensues when exogenous glucocorticoid therapy suppresses pituitary ACTH secretion. Secondly, circulating antibodies against steroid 21-hydroxylase are very specific for autoimmune Addison's disease and provide a marker of the humoral immune response [21] . Lastly, there already exists extremely sensitive immunometric and GC-MS methodology for assay of numerous steroids, meaning that nanomolar changes in adrenal steroidogenesis can be reliably detected in serum.
In our pilot study, six newly diagnosed patients were treated with B cell depletion, leading to a drop in serum 21-hydroxylase antibodies (Fig. 2) [19 & ]. Furthermore, one patient had a progressive rise in serum cortisol, such that she was able to discontinue steroid replacement 15 months after her initial B cell depletion treatment and subsequently had an extended 17-month 'remission' of her adrenal failure. This study provides proof of principle that Addison's disease is potentially remediable when first diagnosed [19 & ]. The importance of this observation lies in the fact that the majority of Addison's patients have a low but detectable serum cortisol at diagnosis suggesting persistence of steroidogenic cells at this stage, which have the potential to be rescued by appropriate immunomodulatory therapy.
In a further attempt to explore the plasticity of adrenal progenitor/stem cells in Addison's disease, we performed a 20-week study of high-dose ACTH (tetracosactide) therapy in 13 patients with established autoimmune Addison's disease. Two out of the 13 patients had significant residual adrenal function at baseline, and both had progressive rises in serum cortisol and aldosterone during ACTH therapy [22 & ]. Both were able to stop oral glucocorticoid and mineralocorticoid replacement during the study, but one of the patients had a progressive decline in steroidogenic function once ACTH was discontinued. The other patient remains well with good steroidogenic function and no replacement medications 36 months after ACTH was stopped [22 & ]. This study highlights that residual adrenal function in patients with Addison's disease is important as a future therapeutic target and starts to explain why patients with spontaneous recovery of established Addison's disease have occasionally been reported [23, 24] .
CONCLUSION
Current management of Addison's disease entails several daily doses of hydrocortisone and a single daily dose of fludrocortisone for most patients. In the future, sustained release preparations of hydrocortisone may allow improved well-being and quality of life, as well as being more convenient and potentially reducing the long-term morbidity of chronic glucocorticoid administration. Certain patients may also be suitable for continuous subcutaneous hydrocortisone administration, although the ideal target group remains to be defined. A few studies have started to look at disease-modifying therapies for autoimmune Addison's disease and this may be a fruitful approach, particularly in patients who have a degree of residual adrenal function. 
